SecBot SecBot
8-K ·Filed Nov 9, 2026

ZNTL

Zentalis Pharmaceuticals, Inc.
BEARISH
Impact 5/10
Horizonmonths Processed7d 11h ago SEC0001725160-26-000069
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The delay of the DENALI Part 2 topline readout from year-end 2026 to 1H 2027 pushes back the key catalyst and any potential FDA submission. The August follow-on offering diluted existing holders by ~27% (26.45M shares on 98.3M outstanding). Monitor FDA discussions in 2027 and the DENALI readout for the next major catalyst.

DirectionBearish
Confidencehigh
Horizonmonths

azenosertib

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2 (registration-intent) with Phase 3 confirmatory trial initiated
Time to market
If the DENALI Part 2 readout in 1H 2027 is positive, Zentalis plans to discuss an accelerated approval pathway with the FDA in 2027. Under an accelerated approval scenario, a potential FDA decision could come in 2028 at the earliest, though the timeline is uncertain and depends on regulatory feedback.
Next catalyst
None dated

What to watchThe next major catalyst is the DENALI Part 2 topline readout expected in 1H 2027 (roughly 2-7 months away). A positive readout could support an accelerated approval filing with the FDA; a negative or mixed readout would likely devastate the stock given Zentalis is a single-asset company. The August 2026 delay from year-end 2026 to 1H 2027 was a negative signal, and the stock now trades at $1.74, well below the $3.50 August offering price. Monitor FDA discussions in 2027 and any pre-readout data disclosures.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.80
T+0 close · Nov 9, 2026 · via day close
Latest settled
+5.00%
T+1 · $1.89 · next T+5 in 3h
Vs SPY
+3.68%
α at T+1
Latest observation
−8.17%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $1.80entry
  2. T+1 · 6d ago +5.00%α +3.68% · $1.89
  3. T+4 · todayOpen
  4. T+5 · in 3h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis reported Q3 2026 net loss of $28.8M ($0.34 per share), narrower than the $0.52 consensus estimate, with cash of $228.9M providing runway into 1H 2028. The DENALI Part 2 topline readout was pushed to 1H 2027 (from year-end 2026), and management plans to discuss accelerated approval with the FDA in 2027, signaling a delay in the regulatory timeline.

Key Financial Metrics

EPS
−$0.34
est −$0.52 · +34.6%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Q3 2026 net loss $28.8M ($0.34/share) vs consensus $-0.52, beat on EPS
  • Cash $228.9M as of Sep 30, 2026, including $86.9M net from Aug 2026 follow-on offering of 26.45M shares
  • DENALI Part 2 topline readout delayed from year-end 2026 to 1H 2027
  • Management plans to discuss DENALI data with FDA in 2027 to assess accelerated approval opportunity
  • DENALI Part 1b OS data: 15.9 months median OS in Cyclin E1-positive vs 7.5 months in negative patients
  • Follow-on equity offering of 26.45M shares completed in August 2026, raising $86.9M net proceeds

Financial Impact

Net loss of $28.8M in Q3 2026, cash burn of ~$17M from Jun 30 to Sep 30 2026 (excluding offering proceeds), $86.9M raised in follow-on offering

net losscash positiondilution

Risk Factors

  • DENALI Part 2 topline readout delayed to 1H 2027, pushing back potential regulatory submission
  • Significant dilution from August 2026 follow-on offering (26.45M shares)
  • No approved products; pre-revenue clinical-stage biotech with ongoing operating losses
  • Accelerated approval pathway uncertain pending FDA feedback and evolving treatment landscape

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001725160-26-000069
Document: zntlq32026corporatedeck.htm0001725160-26-000069
Document: zntl-20261109.htm0001725160-26-000069
Document: 0001725160-26-000069-index-headers.html0001725160-26-000069
Document: 0001725160-26-000069-index.html0001725160-26-000069
Document: 0001725160-26-000069.txt0001725160-26-000069
8-K Data (Synthetic)0001725160-26-000069

Track record

18 reports on ZNTL

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Viewing Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 5h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026